Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

Pages

165 results
4:16 PM, Dec 21, 2017  |  BC Week In Review | Company News  |  Deals

Confo in GPCRs deals with Roche, Lundbeck

granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to its small molecule agonists against an undisclosed GPCR
declined to disclose details. Confo's Confobodies mimic the role of the G protein to stabilize GPCRs …
began a separate discovery collaboration with H. Lundbeck A/S (CSE:LUN) centered on two other undisclosed GPCRs …
1:38 PM, Jul 07, 2017  |  BC Week In Review | Company News  |  Deals

Heptares and NYU to discover GPCRs to treat cancer

University School of Medicine (New York, N.Y.) to discover molecules that selectively modulate an undisclosed GPCR
6:38 PM, May 04, 2017  |  BC Week In Review | Company News  |  Deals

Sosei gets option to acquire MiNA

said the deal is consistent with its strategy to identify technologies that could complement its GPCR-targeted …
9:25 AM, Mar 17, 2017  |  BC Week In Review | Company News  |  Deals

Sosei, Daiichi deal

Ltd. subsidiary and Daiichi Sankyo partnered to discover and develop small molecules against an undisclosed GPCR
1:20 PM, Feb 03, 2017  |  BC Week In Review | Company News  |  Deals

Abilita deal

to use its EMP membrane protein evolution platform to discover and develop proteins that target GPCRs …
12:32 PM, Feb 03, 2017  |  BC Week In Review | Company News  |  Deals

Sosei, University of Cambridge deal

years to discover molecules that target and modulate apelin receptor ( APLNR ; APJ), a GPCR
of Heptares’ ORBIT program, which aims to dedicate its structure-based drug design expertise to developing GPCRs …
1:34 PM, Dec 16, 2016  |  BC Week In Review | Company News  |  Deals

Pfizer, Ab Initio deal

partnered to use Ab Initio's platform to discover antibodies against an undisclosed target in the GPCR
11:36 AM, Dec 02, 2016  |  BC Week In Review | Company News  |  Deals

Heptares, G7 deal

and development company G7 for CHF12 million ($11.9 million) in cash. The acquisition combines Heptares' GPCR
targeting technology StaR with G7's SaBRE and CHESS technologies, which stabilize GPCRs. G7 will be a …
12:00 AM, Jan 18, 2016  |  BC Week In Review | Company News  |  Deals

Arena, Boehringer Ingelheim deal

Boehringer exclusive, worldwide rights to develop and commercialize undisclosed oral, small molecules against an undisclosed GPCR
12:00 AM, Oct 12, 2015  |  BC Week In Review | Company News  |  Deals

ex scientia, Sumitomo Dainippon deal

of the first bispecific compound covered under the deal. The dual agonist selectively activates two GPCR

Pages